Adding the approved HCV protease inhibitor
telaprevir (Incivo or Incivek) to pegylated interferon and
ribavirin can increase sustained viral response rates even for difficult-to-treat
liver transplant recipients, but adverse events are common, researchers reported
at the 48th International Liver Congress (EASL 2013) last month in
While many hepatitis C patients await interferon-free
direct-acting antiviral regimens, others have advanced liver disease and need
treatment now. This group includes liver transplant recipients, as HCV almost
always recurs and infects the new liver in the absence of treatment.
Elizabeth Verna from Columbia University and fellow
investigators with the CRUSH-C study evaluated triple therapy in a cohort of
liver transplant recipients at six US centres.